Sino Biological Introduces ProPure™ Endotoxin-Free Proteins, Enhancing Research and Therapeutic Development

Sino Biological US, Inc. has announced the launch of ProPure™, a groundbreaking line of ultra-pure, endotoxin-free recombinant proteins, manufactured at its Center for Bioprocessing (C4B) facility in Houston, Texas. These proteins are designed to meet the stringent requirements of immunology research, vaccine development, and therapeutic protein manufacturing, among other sensitive applications.

The ProPure™ proteins are produced using advanced purification technologies, ensuring endotoxin levels are below the limit of quantification. This achievement is significant for research and therapeutic applications where even minimal endotoxin contamination can affect outcomes. Dr. Rob Burgess, Chief Business Officer at Sino Biological US, emphasized the company's dedication to scientific excellence and product safety, highlighting how ProPure™ supports high-quality standards in both basic and translational science.

This launch reflects Sino Biological's commitment to bioprocessing innovation and its support for the global life sciences community. The C4B facility not only offers standard protein products but also provides customized development services to meet specific research and production needs. For more information, visit https://www.sinobiological.com.